Objective: The study aimed to investigate the complement C1q test results of HIV/AIDS patients in clinical application before and after treatments. Methods: We collected HIV/AIDS patients’ serum specimens storing at ...Objective: The study aimed to investigate the complement C1q test results of HIV/AIDS patients in clinical application before and after treatments. Methods: We collected HIV/AIDS patients’ serum specimens storing at -80 centigrade freezer in cryogenic refrigerator for standby. After samples quantity met the requirements of selected cases unified, complement C1q was detected by immune transmission turbidity method, and compared the differences in complement C1q of HIV/AIDS patients in test results before and after treatment. In the collection of 96 cases selected samples, concentration of complement C1q was 157.95 ± 31.46 mg/L before treatment, while after treatment, it was 147.26 ± 28.76 mg/L. Comparing the results before and after treatment,?t?= 2.45726,?P?= 0.01049, the difference was statistically significant. Concentration of complement C1q increased after treatment with 33 cases. There were 63 cases reducing. Through statistical analysis on the data from the number of reducing and increasing cases, chi-square = 18.75,?P?= 0.00356, the difference was statistically significant. Complement C1q detection in the treatment of patients with HIV/AIDS had an important clinical significance in the process. The analysis of the concentration changes before and after treatment was clinically significant for drug selection and monitoring disease progression and curative effects, which would be worth further researching.展开更多
目的探究血清网膜素-1(Omentin-1)、补体/C1q肿瘤坏死因子相关蛋白9(CTRP-9)水平与急性脑梗死(ACI)神经功能康复的相关性。方法选取2022年11月至2024年2月于该院治疗的ACI患者106例作为研究组,其中包括ACI神经功能康复良好患者62例(良好...目的探究血清网膜素-1(Omentin-1)、补体/C1q肿瘤坏死因子相关蛋白9(CTRP-9)水平与急性脑梗死(ACI)神经功能康复的相关性。方法选取2022年11月至2024年2月于该院治疗的ACI患者106例作为研究组,其中包括ACI神经功能康复良好患者62例(良好组)和康复不良患者44例(不良组)。采用酶联免疫吸附试验检测所有研究对象的血清Omentin-1、CTRP-9水平;采用Spearman相关性分析血清Omentin-1、CTRP-9水平与ACI患者入院时的美国国立卫生研究院卒中量表(NIHSS)评分及脑梗死体积的相关性;采用多因素Logistic回归分析ACI患者神经功能康复不良的影响因素;采用受试者工作特征(ROC)曲线分析血清Omentin-1、CTRP-9水平对ACI患者神经功能康复不良的诊断价值。结果良好组血清Omentin-1、CTRP-9水平明显高于不良组(P<0.05),入院时NIHSS评分、脑梗死面积和发病90 d时改良Rankin量表(mRS)评分明显低于不良组(P<0.05);Spearman相关性分析显示,血清Omentin-1、CTRP-9水平与90 d mRS评分呈负相关(r=-0.648,-0.573,均P<0.001);多因素Logistic回归分析结果显示,90 d mRS评分是ACI患者神经功能康复不良的危险因素(P<0.05),血清Omentin-1、CTRP-9水平是ACI患者神经功能康复不良的保护因素(P<0.05);ROC曲线分析结果显示,血清Omentin-1、CTRP-9水平诊断ACI患者神经功能康复不良的曲线下面积(AUC)为0.843、0.828,二者联合诊断的AUC为0.937,明显大于二者单独诊断(Z_(二者联合-Omentin-1)=2.321,P=0.020;Z_(二者联合-CTRP-9)=2.532,P=0.011)。结论ACI神经功能康复不良患者血清Omentin-1、CTRP-9水平明显降低,且Omentin-1、CTRP-9水平与90 d mRS评分呈负相关,与神经功能康复情况密切相关。展开更多
文摘Objective: The study aimed to investigate the complement C1q test results of HIV/AIDS patients in clinical application before and after treatments. Methods: We collected HIV/AIDS patients’ serum specimens storing at -80 centigrade freezer in cryogenic refrigerator for standby. After samples quantity met the requirements of selected cases unified, complement C1q was detected by immune transmission turbidity method, and compared the differences in complement C1q of HIV/AIDS patients in test results before and after treatment. In the collection of 96 cases selected samples, concentration of complement C1q was 157.95 ± 31.46 mg/L before treatment, while after treatment, it was 147.26 ± 28.76 mg/L. Comparing the results before and after treatment,?t?= 2.45726,?P?= 0.01049, the difference was statistically significant. Concentration of complement C1q increased after treatment with 33 cases. There were 63 cases reducing. Through statistical analysis on the data from the number of reducing and increasing cases, chi-square = 18.75,?P?= 0.00356, the difference was statistically significant. Complement C1q detection in the treatment of patients with HIV/AIDS had an important clinical significance in the process. The analysis of the concentration changes before and after treatment was clinically significant for drug selection and monitoring disease progression and curative effects, which would be worth further researching.
文摘目的探究血清网膜素-1(Omentin-1)、补体/C1q肿瘤坏死因子相关蛋白9(CTRP-9)水平与急性脑梗死(ACI)神经功能康复的相关性。方法选取2022年11月至2024年2月于该院治疗的ACI患者106例作为研究组,其中包括ACI神经功能康复良好患者62例(良好组)和康复不良患者44例(不良组)。采用酶联免疫吸附试验检测所有研究对象的血清Omentin-1、CTRP-9水平;采用Spearman相关性分析血清Omentin-1、CTRP-9水平与ACI患者入院时的美国国立卫生研究院卒中量表(NIHSS)评分及脑梗死体积的相关性;采用多因素Logistic回归分析ACI患者神经功能康复不良的影响因素;采用受试者工作特征(ROC)曲线分析血清Omentin-1、CTRP-9水平对ACI患者神经功能康复不良的诊断价值。结果良好组血清Omentin-1、CTRP-9水平明显高于不良组(P<0.05),入院时NIHSS评分、脑梗死面积和发病90 d时改良Rankin量表(mRS)评分明显低于不良组(P<0.05);Spearman相关性分析显示,血清Omentin-1、CTRP-9水平与90 d mRS评分呈负相关(r=-0.648,-0.573,均P<0.001);多因素Logistic回归分析结果显示,90 d mRS评分是ACI患者神经功能康复不良的危险因素(P<0.05),血清Omentin-1、CTRP-9水平是ACI患者神经功能康复不良的保护因素(P<0.05);ROC曲线分析结果显示,血清Omentin-1、CTRP-9水平诊断ACI患者神经功能康复不良的曲线下面积(AUC)为0.843、0.828,二者联合诊断的AUC为0.937,明显大于二者单独诊断(Z_(二者联合-Omentin-1)=2.321,P=0.020;Z_(二者联合-CTRP-9)=2.532,P=0.011)。结论ACI神经功能康复不良患者血清Omentin-1、CTRP-9水平明显降低,且Omentin-1、CTRP-9水平与90 d mRS评分呈负相关,与神经功能康复情况密切相关。
